Busulfex Injection Available In The U.S. For Chronic
MINNEAPOLIS, MN -- Feb. 23, 1999 -- Orphan Medical, Inc.’s Busulfex(TM)
(busulfan) Injection is now available in the United States for use in
combination with cyclophosphamide as a conditioning regimen prior to allogeneic
hematopoietic progenitor cell transplantation for chronic myelogenous leukemia
Orphan Medical also announced that Tzamal Pharma LTD has the right to
distribute Busulfex in Israel. A privately owned company, Tzamal Pharma markets
and distributes orphan drugs in Israel.
The most common adverse events in patients treated with Busulfex include
profound myelosuppression in 100 percent of patients, nausea (97 percent,
mild/moderate in 92 percent), stomatitis (97 percent, grade III in 26 percent),
vomiting (95 percent, all mild/moderate) and anorexia (85 percent). The type of
adverse events seen with Busulfex did not differ from those seen with oral
busulfan in the transplant setting.